Study participants characteristics by analysis sample
| Characteristic . | ARIC (n = 729) . | FHS (n = 6771) . | MONICA/KORA (n = 1625) . |
|---|---|---|---|
| Age, y, mean ± SD | 56.5 ± 5.1 | 49.4 ± 13.8 | 52.5 ± 10.1 |
| Women, % | 34.8 | 53.4 | 50.7 |
| Current smoking, % | 30.3 | 15.5 | 15.4 |
| Body mass index, kg/m2, mean ± SD | 27.0 ± 4.6 | 27.4 ± 5.5 | 27.3 ± 4.1 |
| Waist, cm, mean ± SD | 97.5 ± 12.4 | 96.0 ± 15.0 | 90.3 ± 12.4 |
| Systolic blood pressure, mm Hg, mean ± SD | 122 ± 18 | 121 ± 17 | 133 ± 18 |
| Total/HDL cholesterol, ratio, mean ± SD | 5.0 ± 1.9 | 3.9 ± 1.4 | 4.7 ± 1.7 |
| Glucose, mg/dL, mean ± SD | 107 ± 33 | 99 ± 23 | 100 ± 34 |
| Triglycerides, mg/dL, mean ± SD | 143 ± 89 | 125 ± 91 | 180 ± 142 |
| Diabetes, % | 11.8 | 7.5 | 4.4 |
| Hypertension treatment, % | 20.5 | 19.5 | 16.9 |
| Lipid treatment, % | 3.0 | 13.4 | 4.2 |
| Aspirin intake, %* | — | 18.5 | 4.6 |
| Hormone replacement (women), % | 19.7 | 16.5 | 21.3 |
| Prevalent cardiovascular disease, % | 4.2 | 6.2 | 1.5 |
| MCP-1, pg/mL, median (25th-75th percentile) | |||
| Plasma | 392 (341-447) | — | 142 (119-170) |
| Serum | — | 323 (263-401) | 312 (252-384) |
| MCP-1, ln transformed mean ± SD† | |||
| Plasma | 5.97 ± 0.23 | — | 4.98 ± 0.35 |
| Serum | — | 5.78 ± 0.34 | 5.74 ± 0.35 |
| Characteristic . | ARIC (n = 729) . | FHS (n = 6771) . | MONICA/KORA (n = 1625) . |
|---|---|---|---|
| Age, y, mean ± SD | 56.5 ± 5.1 | 49.4 ± 13.8 | 52.5 ± 10.1 |
| Women, % | 34.8 | 53.4 | 50.7 |
| Current smoking, % | 30.3 | 15.5 | 15.4 |
| Body mass index, kg/m2, mean ± SD | 27.0 ± 4.6 | 27.4 ± 5.5 | 27.3 ± 4.1 |
| Waist, cm, mean ± SD | 97.5 ± 12.4 | 96.0 ± 15.0 | 90.3 ± 12.4 |
| Systolic blood pressure, mm Hg, mean ± SD | 122 ± 18 | 121 ± 17 | 133 ± 18 |
| Total/HDL cholesterol, ratio, mean ± SD | 5.0 ± 1.9 | 3.9 ± 1.4 | 4.7 ± 1.7 |
| Glucose, mg/dL, mean ± SD | 107 ± 33 | 99 ± 23 | 100 ± 34 |
| Triglycerides, mg/dL, mean ± SD | 143 ± 89 | 125 ± 91 | 180 ± 142 |
| Diabetes, % | 11.8 | 7.5 | 4.4 |
| Hypertension treatment, % | 20.5 | 19.5 | 16.9 |
| Lipid treatment, % | 3.0 | 13.4 | 4.2 |
| Aspirin intake, %* | — | 18.5 | 4.6 |
| Hormone replacement (women), % | 19.7 | 16.5 | 21.3 |
| Prevalent cardiovascular disease, % | 4.2 | 6.2 | 1.5 |
| MCP-1, pg/mL, median (25th-75th percentile) | |||
| Plasma | 392 (341-447) | — | 142 (119-170) |
| Serum | — | 323 (263-401) | 312 (252-384) |
| MCP-1, ln transformed mean ± SD† | |||
| Plasma | 5.97 ± 0.23 | — | 4.98 ± 0.35 |
| Serum | — | 5.78 ± 0.34 | 5.74 ± 0.35 |